IL2 and atherosclerosis: Indeed, a combination therapy with anti‐CD3 antibody and IL‐2/anti‐IL‐2 monoclonal antibody complex aimed at increasing the ratio of Tregs to pathogenic effector T cells inhibited atherosclerosis in the ApoE−/− model system.35